Skip to main content
. 2013 Apr 15;2(2):77–83. doi: 10.1016/j.jbo.2013.03.001

Fig. 2.

Fig. 2

Summary of respondent answers, scenarios 1–5. Summary of responses to Scenarios 1–5. ‘⁎’ Scenario 5 pertains only to respondents who use bone targeted agents to treat prostate cancer patients (n=23).